Irina V. Lebedeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Irina V. Lebedeva has a total of 124 co-authors. Here are the top co-authors by number of shared publications:
Pankaj Gupta
Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298, USA
5 shared publicationsDevanand Sarkar
Department of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA 23298, USA
4 shared publications- Paul B. Fisher
Department of Urology, Herbert Irving Comprehensive Cancer Center, Columbia University, College of Physicians and Surgeons, New York, New York
4 shared publications - Paul Dent
Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA
4 shared publications - Devanand Sarkar
Virginia Commonwealth University, VCU Medical Center, School of Medicine
3 shared publications Luni Emdad
Department of Neurosurgery, Mount Sinai School of Medicine, New York, NY 10029, USA
3 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 2 February 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (6)
Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers
Delta-like ligand 3 (DLL3) is a tumor-selective cell surface protein upregulated in high-grade neuroendocrine tumors, including small-cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC). Here, we report on the development of anti-DLL3 radioimmunoconjugates for use as either a diagnostic imaging tracer based on the positron-emitter zirconium-89 ( 89 Zr) or a therapeutic agent utilizing the beta-emitter lutetium-177 ( 177 Lu). To begin, we generated a panel of human monoclonal antibodies targeting human DLL3 by immunizing transgenic mice engineered with a human immunoglobulin repertoire. The panel was extensively screened to identify high-affinity internalizing monoclonal antibodies (mAbs) recognizing a diversity of DLL3 epitopes. Select mAbs were reformatted as fully human Fab-arm exchange-deficient IgG4 to reduce effector function and then produced by recombinant methods. A pilot immunoPET study was performed in athymic female nude mice bearing human NCI-H82 SCLC tumors to nominate a lead candidate. ImmunoPET identified [ 89 Zr]Zr-DFO-TDI-Y-010 as the top-performing diagnostic tracer, with excellent in vivo biodistribution and tumor-to-background-organ ratios consistently >4. Therapeutic studies with [ 177 Lu]Lu-CHX-A"-DTPA-TDI-Y-010 demonstrated strong antitumor effects, significantly improving ( P 177 Lu]Lu-CHX-A"-DTPA-SC16.56 in two SCLC tumor models (NCI-H82 and Lu149) and achieving comparable overall survival in a NEPC tumor model.
- 2 February 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (6)
Top Cited PapersOpen AccessNext-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers
Delta-like ligand 3 (DLL3) is a tumor-selective cell surface protein upregulated in high-grade neuroendocrine tumors, including small-cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC). Here, we report on the development of anti-DLL3 radioimmunoconjugates for use as either a diagnostic imaging tracer based on the positron-emitter zirconium-89 ( 89 Zr) or a therapeutic agent utilizing the beta-emitter lutetium-177 ( 177 Lu). To begin, we generated a panel of human monoclonal antibodies targeting human DLL3 by immunizing transgenic mice engineered with a human immunoglobulin repertoire. The panel was extensively screened to identify high-affinity internalizing monoclonal antibodies (mAbs) recognizing a diversity of DLL3 epitopes. Select mAbs were reformatted as fully human Fab-arm exchange-deficient IgG4 to reduce effector function and then produced by recombinant methods. A pilot immunoPET study was performed in athymic female nude mice bearing human NCI-H82 SCLC tumors to nominate a lead candidate. ImmunoPET identified [ 89 Zr]Zr-DFO-TDI-Y-010 as the top-performing diagnostic tracer, with excellent in vivo biodistribution and tumor-to-background-organ ratios consistently >4. Therapeutic studies with [ 177 Lu]Lu-CHX-A"-DTPA-TDI-Y-010 demonstrated strong antitumor effects, significantly improving ( P 177 Lu]Lu-CHX-A"-DTPA-SC16.56 in two SCLC tumor models (NCI-H82 and Lu149) and achieving comparable overall survival in a NEPC tumor model.
- Open Access
- 15 May 2023
- Published by Springer Nature in Nature Microbiology
- Vol. 8 (6) , 1051-1063
Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies
Human monoclonal antibodies (mAbs) that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been isolated from convalescent individuals and developed into therapeutics for SARS-CoV-2 infection. However, therapeutic mAbs for SARS-CoV-2 have been rendered obsolete by the emergence of mAb-resistant virus variants. Here we report the generation of a set of six human mAbs that bind the human angiotensin-converting enzyme-2 (hACE2) receptor, rather than the SARS-CoV-2 spike protein. We show that these antibodies block infection by all hACE2 binding sarbecoviruses tested, including SARS-CoV-2 ancestral, Delta and Omicron variants at concentrations of ~7–100 ng ml−1. These antibodies target an hACE2 epitope that binds to the SARS-CoV-2 spike, but they do not inhibit hACE2 enzymatic activity nor do they induce cell-surface depletion of hACE2. They have favourable pharmacology, protect hACE2 knock-in mice against SARS-CoV-2 infection and should present a high genetic barrier to the acquisition of resistance. These antibodies should be useful prophylactic and treatment agents against any current or future SARS-CoV-2 variants and might be useful to treat infection with any hACE2-binding sarbecoviruses that emerge in the future.
- 15 May 2023
- Published by Springer Nature in Nature Microbiology
- Vol. 8 (6) , 1051-1063
Open AccessPan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies
Human monoclonal antibodies (mAbs) that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been isolated from convalescent individuals and developed into therapeutics for SARS-CoV-2 infection. However, therapeutic mAbs for SARS-CoV-2 have been rendered obsolete by the emergence of mAb-resistant virus variants. Here we report the generation of a set of six human mAbs that bind the human angiotensin-converting enzyme-2 (hACE2) receptor, rather than the SARS-CoV-2 spike protein. We show that these antibodies block infection by all hACE2 binding sarbecoviruses tested, including SARS-CoV-2 ancestral, Delta and Omicron variants at concentrations of ~7–100 ng ml−1. These antibodies target an hACE2 epitope that binds to the SARS-CoV-2 spike, but they do not inhibit hACE2 enzymatic activity nor do they induce cell-surface depletion of hACE2. They have favourable pharmacology, protect hACE2 knock-in mice against SARS-CoV-2 infection and should present a high genetic barrier to the acquisition of resistance. These antibodies should be useful prophylactic and treatment agents against any current or future SARS-CoV-2 variants and might be useful to treat infection with any hACE2-binding sarbecoviruses that emerge in the future.
- Open Access
- 5 August 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (8) , 1-11
Precision genetic cellular models identify therapies protective against ER stress
Rare monogenic disorders often share molecular etiologies involved in the pathogenesis of common diseases. Congenital disorders of glycosylation (CDG) and deglycosylation (CDDG) are rare pediatric disorders with symptoms that range from mild to life threatening. A biological mechanism shared among CDG and CDDG as well as more common neurodegenerative diseases such as Alzheimer’s disease and amyotrophic lateral sclerosis, is endoplasmic reticulum (ER) stress. We developed isogenic human cellular models of two types of CDG and the only known CDDG to discover drugs that can alleviate ER stress. Systematic phenotyping confirmed ER stress and identified elevated autophagy among other phenotypes in each model. We screened 1049 compounds and scored their ability to correct aberrant morphology in each model using an agnostic cell-painting assay based on >300 cellular features. This primary screen identified multiple compounds able to correct morphological phenotypes. Independent validation shows they also correct cellular phenotypes and alleviate each of the ER stress markers identified in each model. Many of the active compounds are associated with microtubule dynamics, which points to new therapeutic opportunities for both rare and more common disorders presenting with ER stress, such as Alzheimer’s disease and amyotrophic lateral sclerosis.
- 5 August 2021
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (8) , 1-11
Open AccessPrecision genetic cellular models identify therapies protective against ER stress
Rare monogenic disorders often share molecular etiologies involved in the pathogenesis of common diseases. Congenital disorders of glycosylation (CDG) and deglycosylation (CDDG) are rare pediatric disorders with symptoms that range from mild to life threatening. A biological mechanism shared among CDG and CDDG as well as more common neurodegenerative diseases such as Alzheimer’s disease and amyotrophic lateral sclerosis, is endoplasmic reticulum (ER) stress. We developed isogenic human cellular models of two types of CDG and the only known CDDG to discover drugs that can alleviate ER stress. Systematic phenotyping confirmed ER stress and identified elevated autophagy among other phenotypes in each model. We screened 1049 compounds and scored their ability to correct aberrant morphology in each model using an agnostic cell-painting assay based on >300 cellular features. This primary screen identified multiple compounds able to correct morphological phenotypes. Independent validation shows they also correct cellular phenotypes and alleviate each of the ER stress markers identified in each model. Many of the active compounds are associated with microtubule dynamics, which points to new therapeutic opportunities for both rare and more common disorders presenting with ER stress, such as Alzheimer’s disease and amyotrophic lateral sclerosis.
- Open Access
Precision genetic cellular models identify therapies protective against endoplasmic reticulum stress
Congenital disorders of glycosylation (CDG) and deglycosylation (CDDG) are a collection of rare pediatric disorders with symptoms that range from mild to life threatening. They typically affect multiple organ systems and usually present with neurological abnormalities including hypotonia, cognitive impairment, and intractable seizures. Several genes have been implicated in the thirty-six types of CDG, but currently NGLY1 is the only known CDDG gene. A common biological mechanism among CDG types and in CDDG is endoplasmic reticulum (ER) stress. Here, we develop two isogenic human cellular models of CDG ( PMM2 , the most prevalent type of CDG, and DPAGT1 ) and of the only CDDG ( NGLY1 ) in an effort to identify drugs that can alleviate ER stress. Systematic phenotyping identified elevated ER stress and autophagy levels among other cellular and morphological phenotypes in each of the cellular models. We screened a complex drug library for compounds able to correct aberrant morphological phenotypes in each of the models using an agnostic phenotypic cell painting assay based on >300 cellular features. The image-based screen identified multiple candidate compounds able to correct aberrant morphology, and we show a subset of these are able to correct cellular and molecular defects in each of the models. These results provide new directions for the treatment of rare diseases of glycosylation and deglycosylation and a framework for new drug screening paradigms for more common neurodegenerative diseases characterized by ER stress. Summary sentence: Novel drug screening modality identifies compounds that correct aberrant molecular phenotypes in precision cellular models of glycosylation defects.
Open AccessPrecision genetic cellular models identify therapies protective against endoplasmic reticulum stress
Congenital disorders of glycosylation (CDG) and deglycosylation (CDDG) are a collection of rare pediatric disorders with symptoms that range from mild to life threatening. They typically affect multiple organ systems and usually present with neurological abnormalities including hypotonia, cognitive impairment, and intractable seizures. Several genes have been implicated in the thirty-six types of CDG, but currently NGLY1 is the only known CDDG gene. A common biological mechanism among CDG types and in CDDG is endoplasmic reticulum (ER) stress. Here, we develop two isogenic human cellular models of CDG ( PMM2 , the most prevalent type of CDG, and DPAGT1 ) and of the only CDDG ( NGLY1 ) in an effort to identify drugs that can alleviate ER stress. Systematic phenotyping identified elevated ER stress and autophagy levels among other cellular and morphological phenotypes in each of the cellular models. We screened a complex drug library for compounds able to correct aberrant morphological phenotypes in each of the models using an agnostic phenotypic cell painting assay based on >300 cellular features. The image-based screen identified multiple candidate compounds able to correct aberrant morphology, and we show a subset of these are able to correct cellular and molecular defects in each of the models. These results provide new directions for the treatment of rare diseases of glycosylation and deglycosylation and a framework for new drug screening paradigms for more common neurodegenerative diseases characterized by ER stress. Summary sentence: Novel drug screening modality identifies compounds that correct aberrant molecular phenotypes in precision cellular models of glycosylation defects.
- Open Access
- 1 October 2017
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 16 (10) , 2069-2082
PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature
PI3K/AKT and NOTCH1 signaling pathways are frequently dysregulated in T-cell acute lymphoblastic leukemias (T-ALL). Although we have shown that the combined activities of the class I PI3K isoforms p110γ and p110δ play a major role in the development and progression of PTEN-null T-ALL, it has yet to be determined whether their contribution to leukemogenic programing is unique from that associated with NOTCH1 activation. Using an Lmo2-driven mouse model of T-ALL in which both the PI3K/AKT and NOTCH1 pathways are aberrantly upregulated, we now demonstrate that the combined activities of PI3Kγ/δ have both overlapping and distinct roles from NOTCH1 in generating T-ALL disease signature and in promoting tumor cell growth. Treatment of diseased animals with either a dual PI3Kγ/δ or a γ-secretase inhibitor reduced tumor burden, prolonged survival, and induced proapoptotic pathways. Consistent with their similar biological effects, both inhibitors downregulated genes involved in cMYC-dependent metabolism in gene set enrichment analyses. Furthermore, overexpression of cMYC in mice or T-ALL cell lines conferred resistance to both inhibitors, suggesting a point of pathway convergence. Of note, interrogation of transcriptional regulators and analysis of mitochondrial function showed that PI3Kγ/δ activity played a greater role in supporting the disease signature and critical bioenergetic pathways. Results provide insight into the interrelationship between T-ALL oncogenic networks and the therapeutic efficacy of dual PI3Kγ/δ inhibition in the context of NOTCH1 and cMYC signaling. Mol Cancer Ther; 16(10); 2069–82. ©2017 AACR.
- 1 October 2017
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 16 (10) , 2069-2082
Open AccessPI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature
PI3K/AKT and NOTCH1 signaling pathways are frequently dysregulated in T-cell acute lymphoblastic leukemias (T-ALL). Although we have shown that the combined activities of the class I PI3K isoforms p110γ and p110δ play a major role in the development and progression of PTEN-null T-ALL, it has yet to be determined whether their contribution to leukemogenic programing is unique from that associated with NOTCH1 activation. Using an Lmo2-driven mouse model of T-ALL in which both the PI3K/AKT and NOTCH1 pathways are aberrantly upregulated, we now demonstrate that the combined activities of PI3Kγ/δ have both overlapping and distinct roles from NOTCH1 in generating T-ALL disease signature and in promoting tumor cell growth. Treatment of diseased animals with either a dual PI3Kγ/δ or a γ-secretase inhibitor reduced tumor burden, prolonged survival, and induced proapoptotic pathways. Consistent with their similar biological effects, both inhibitors downregulated genes involved in cMYC-dependent metabolism in gene set enrichment analyses. Furthermore, overexpression of cMYC in mice or T-ALL cell lines conferred resistance to both inhibitors, suggesting a point of pathway convergence. Of note, interrogation of transcriptional regulators and analysis of mitochondrial function showed that PI3Kγ/δ activity played a greater role in supporting the disease signature and critical bioenergetic pathways. Results provide insight into the interrelationship between T-ALL oncogenic networks and the therapeutic efficacy of dual PI3Kγ/δ inhibition in the context of NOTCH1 and cMYC signaling. Mol Cancer Ther; 16(10); 2069–82. ©2017 AACR.
- Open Access
- 22 July 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (7) , e22429
Sensitive and Specific Fluorescent Probes for Functional Analysis of the Three Major Types of Mammalian ABC Transporters
An underlying mechanism for multi drug resistance (MDR) is up-regulation of the transmembrane ATP-binding cassette (ABC) transporter proteins. ABC transporters also determine the general fate and effect of pharmaceutical agents in the body. The three major types of ABC transporters are MDR1 (P-gp, P-glycoprotein, ABCB1), MRP1/2 (ABCC1/2) and BCRP/MXR (ABCG2) proteins. Flow cytometry (FCM) allows determination of the functional expression levels of ABC transporters in live cells, but most dyes used as indicators (rhodamine 123, DiOC2(3), calcein-AM) have limited applicability as they do not detect all three major types of ABC transporters. Dyes with broad coverage (such as doxorubicin, daunorubicin and mitoxantrone) lack sensitivity due to overall dimness and thus may yield a significant percentage of false negative results. We describe two novel fluorescent probes that are substrates for all three common types of ABC transporters and can serve as indicators of MDR in flow cytometry assays using live cells. The probes exhibit fast internalization, favorable uptake/efflux kinetics and high sensitivity of MDR detection, as established by multidrug resistance activity factor (MAF) values and Kolmogorov-Smirnov statistical analysis. Used in combination with general or specific inhibitors of ABC transporters, both dyes readily identify functional efflux and are capable of detecting small levels of efflux as well as defining the type of multidrug resistance. The assay can be applied to the screening of putative modulators of ABC transporters, facilitating rapid, reproducible, specific and relatively simple functional detection of ABC transporter activity, and ready implementation on widely available instruments.
- 22 July 2011
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (7) , e22429
Open AccessSensitive and Specific Fluorescent Probes for Functional Analysis of the Three Major Types of Mammalian ABC Transporters
An underlying mechanism for multi drug resistance (MDR) is up-regulation of the transmembrane ATP-binding cassette (ABC) transporter proteins. ABC transporters also determine the general fate and effect of pharmaceutical agents in the body. The three major types of ABC transporters are MDR1 (P-gp, P-glycoprotein, ABCB1), MRP1/2 (ABCC1/2) and BCRP/MXR (ABCG2) proteins. Flow cytometry (FCM) allows determination of the functional expression levels of ABC transporters in live cells, but most dyes used as indicators (rhodamine 123, DiOC2(3), calcein-AM) have limited applicability as they do not detect all three major types of ABC transporters. Dyes with broad coverage (such as doxorubicin, daunorubicin and mitoxantrone) lack sensitivity due to overall dimness and thus may yield a significant percentage of false negative results. We describe two novel fluorescent probes that are substrates for all three common types of ABC transporters and can serve as indicators of MDR in flow cytometry assays using live cells. The probes exhibit fast internalization, favorable uptake/efflux kinetics and high sensitivity of MDR detection, as established by multidrug resistance activity factor (MAF) values and Kolmogorov-Smirnov statistical analysis. Used in combination with general or specific inhibitors of ABC transporters, both dyes readily identify functional efflux and are capable of detecting small levels of efflux as well as defining the type of multidrug resistance. The assay can be applied to the screening of putative modulators of ABC transporters, facilitating rapid, reproducible, specific and relatively simple functional detection of ABC transporter activity, and ready implementation on widely available instruments.
- 1 November 2010
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 128 (2) , 375-384
The development of MDA-7/IL-24 as a cancer therapeutic
- 1 November 2010
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 128 (2) , 375-384
The development of MDA-7/IL-24 as a cancer therapeutic
- 12 February 2008
- Published by Wiley in Journal of Cellular Physiology
- Vol. 215 (3) , 827-836
Targeted combinatorial therapy of non‐small cell lung carcinoma using a GST‐fusion protein of full‐length or truncated MDA‐7/IL‐24 with Tarceva
Melanoma differentiation associated gene‐7/interleukin‐24 (mda‐7/IL‐24), a cytokine belonging to the IL‐10 family, displays cancer‐specific apoptosis‐inducing properties when delivered by a replication‐incompetent adenovirus (Ad.mda‐7) or as a GST‐tagged recombinant protein (GST‐MDA‐7). Previous studies demonstrated that an adenovirus expressing M4, a truncated version of MDA‐7/IL‐24 containing amino acid residues 104–206, also induced similar cancer‐specific apoptosis. We generated recombinant GST‐M4 proteins and examined the potency of GST‐MDA‐7 and GST‐M4 on a panel of epidermal growth factor receptor (EGFR) wild type and mutant non‐small cell lung carcinoma (NSCLC) cells either as a single agent or in combination with a reversible EGFR inhibitor, Tarceva. The combination of either GST‐MDA‐7 or GST‐M4 (∼0.1 µM) and Tarceva (10 µM), at sub‐optimal apoptosis‐inducing concentrations synergistically enhanced growth inhibition and apoptosis induction over that observed with either agent alone. The combination treatment also augmented inhibition of EGFR signaling, analyzed by phosphorylation of EGFR and its downstream effectors AKT and ERK1/2, over that with single‐agent therapy. Tarceva enhanced GST‐MDA‐7 and GST‐M4 toxicity in cells expressing mutated EGFR proteins that are resistant to the inhibitory effects of Tarceva. In total, these data suggest that combined treatment of NSCLC cells with an EGFR inhibitor can augment the efficacy of GST‐MDA‐7 and GST‐M4 and that the EGFR inhibitor Tarceva may mediate this combinatorial effect by inhibiting multiple tyrosine kinases in addition to the EGFR. This approach highlights a potential new combinatorial strategy, which may prove beneficial for NSCLC patients with acquired resistance to EGFR inhibitors. J. Cell. Physiol. 215: 827–836, 2008.
- 12 February 2008
- Published by Wiley in Journal of Cellular Physiology
- Vol. 215 (3) , 827-836
Targeted combinatorial therapy of non‐small cell lung carcinoma using a GST‐fusion protein of full‐length or truncated MDA‐7/IL‐24 with Tarceva
Melanoma differentiation associated gene‐7/interleukin‐24 (mda‐7/IL‐24), a cytokine belonging to the IL‐10 family, displays cancer‐specific apoptosis‐inducing properties when delivered by a replication‐incompetent adenovirus (Ad.mda‐7) or as a GST‐tagged recombinant protein (GST‐MDA‐7). Previous studies demonstrated that an adenovirus expressing M4, a truncated version of MDA‐7/IL‐24 containing amino acid residues 104–206, also induced similar cancer‐specific apoptosis. We generated recombinant GST‐M4 proteins and examined the potency of GST‐MDA‐7 and GST‐M4 on a panel of epidermal growth factor receptor (EGFR) wild type and mutant non‐small cell lung carcinoma (NSCLC) cells either as a single agent or in combination with a reversible EGFR inhibitor, Tarceva. The combination of either GST‐MDA‐7 or GST‐M4 (∼0.1 µM) and Tarceva (10 µM), at sub‐optimal apoptosis‐inducing concentrations synergistically enhanced growth inhibition and apoptosis induction over that observed with either agent alone. The combination treatment also augmented inhibition of EGFR signaling, analyzed by phosphorylation of EGFR and its downstream effectors AKT and ERK1/2, over that with single‐agent therapy. Tarceva enhanced GST‐MDA‐7 and GST‐M4 toxicity in cells expressing mutated EGFR proteins that are resistant to the inhibitory effects of Tarceva. In total, these data suggest that combined treatment of NSCLC cells with an EGFR inhibitor can augment the efficacy of GST‐MDA‐7 and GST‐M4 and that the EGFR inhibitor Tarceva may mediate this combinatorial effect by inhibiting multiple tyrosine kinases in addition to the EGFR. This approach highlights a potential new combinatorial strategy, which may prove beneficial for NSCLC patients with acquired resistance to EGFR inhibitors. J. Cell. Physiol. 215: 827–836, 2008.
- 24 October 2007
- Published by Wiley in Journal of Cellular Physiology
- Vol. 215 (2) , 401-409
Progression elevated gene‐3 promoter (PEG‐Prom) confers cancer cell selectivity to human polynucleotide phosphorylase (hPNPaseold‐35)‐mediated growth suppression
The poor prognosis of pancreatic cancer patients using currently available therapies mandates novel therapeutics that combine anti‐neoplastic potency with toxicity‐minimizing cancer specificity. Employing an overlapping pathway screen to identify genes exhibiting coordinated expression as a consequence of terminal cell differentiation and replicative senescence, we identified human polynucleotide phosphorylase (hPNPaseold‐35), a 3′,5′‐exoribonuclease that exhibits robust growth‐suppressing effects in a wide spectrum of human cancers. A limitation to the anti‐neoplastic efficacy of hPNPaseold‐35 relates to its lack of cancer specificity. The promoter of Progression Elevated Gene‐3 (PEG‐Prom), discovered in our laboratory via subtraction hybridization in a transformation progression rodent tumor model functions selectively in a diverse array of human cancer cells, with limited activity in normal cells. An adenovirus constructed with the PEG‐Prom driving expression of hPNPaseold‐35 containing a C‐terminal Hemaglutinin (HA)‐tag (Ad.PEG.hPNPaseold‐35) was shown to induce robust transgene expression, growth suppression, apoptosis, and cell‐cycle arrest in a broad panel of pancreatic cancer cells, with minimal effects in normal immortalized pancreatic cells. hPNPaseold‐35 expression correlated with arrest in the G2/M phase of the cell cycle and up‐regulation of the cyclin‐dependent kinase inhibitors (CDKI) p21CIP1/WAF‐1/MDA‐6 and p27KIP1. In a nude mouse xenograft model, Ad.PEG.hPNPaseold‐35 injections effectively inhibited growth of human pancreatic cancer cells in vivo. These findings support the potential efficacy of combining a cancer‐specific promoter, such as the PEG‐Prom, with a novel anti‐neoplastic agent, such as hPNPaseold‐35, to create a potent, targeted cancer therapeutic, especially for a devastating disease like pancreatic cancer. J. Cell. Physiol. 215: 401–409, 2008.
- 24 October 2007
- Published by Wiley in Journal of Cellular Physiology
- Vol. 215 (2) , 401-409
Progression elevated gene‐3 promoter (PEG‐Prom) confers cancer cell selectivity to human polynucleotide phosphorylase (hPNPaseold‐35)‐mediated growth suppression
The poor prognosis of pancreatic cancer patients using currently available therapies mandates novel therapeutics that combine anti‐neoplastic potency with toxicity‐minimizing cancer specificity. Employing an overlapping pathway screen to identify genes exhibiting coordinated expression as a consequence of terminal cell differentiation and replicative senescence, we identified human polynucleotide phosphorylase (hPNPaseold‐35), a 3′,5′‐exoribonuclease that exhibits robust growth‐suppressing effects in a wide spectrum of human cancers. A limitation to the anti‐neoplastic efficacy of hPNPaseold‐35 relates to its lack of cancer specificity. The promoter of Progression Elevated Gene‐3 (PEG‐Prom), discovered in our laboratory via subtraction hybridization in a transformation progression rodent tumor model functions selectively in a diverse array of human cancer cells, with limited activity in normal cells. An adenovirus constructed with the PEG‐Prom driving expression of hPNPaseold‐35 containing a C‐terminal Hemaglutinin (HA)‐tag (Ad.PEG.hPNPaseold‐35) was shown to induce robust transgene expression, growth suppression, apoptosis, and cell‐cycle arrest in a broad panel of pancreatic cancer cells, with minimal effects in normal immortalized pancreatic cells. hPNPaseold‐35 expression correlated with arrest in the G2/M phase of the cell cycle and up‐regulation of the cyclin‐dependent kinase inhibitors (CDKI) p21CIP1/WAF‐1/MDA‐6 and p27KIP1. In a nude mouse xenograft model, Ad.PEG.hPNPaseold‐35 injections effectively inhibited growth of human pancreatic cancer cells in vivo. These findings support the potential efficacy of combining a cancer‐specific promoter, such as the PEG‐Prom, with a novel anti‐neoplastic agent, such as hPNPaseold‐35, to create a potent, targeted cancer therapeutic, especially for a devastating disease like pancreatic cancer. J. Cell. Physiol. 215: 401–409, 2008.
- 16 November 2006
- Published by Wiley in Journal of Cellular Physiology
- Vol. 210 (2) , 549-559
Combinatorial treatment of non‐small‐cell lung cancers with gefitinib and Ad.mda‐7 enhances apoptosis‐induction and reverses resistance to a single therapy
Activation of the epidermal growth factor receptor (EGFR) contributes to the pathogenesis of non‐small‐cell lung carcinomas (NSCLC) and gefitinib, a selective reversible EGFR inhibitor, is effective in treating patients with NSCLC. However, clinical resistance to gefitinib is a frequent occurrence highlighting the need for improved therapeutic strategies. Melanoma differentiation associated gene‐7 (mda‐7)/Interleukin‐24 (IL‐24) (mda‐7/IL‐24) displays cancer‐selective apoptosis induction when delivered via a replication‐incompetent adenovirus (Ad.mda‐7). In this study, the effect of Ad.mda‐7 infection, either alone or in combination with gefitinib, was analyzed in a panel of NSCLC cell lines carrying wild‐type EGFR (H‐460 and H‐2030) or mutant EGFR (H‐1650 and H‐1975). While H‐2030 and H‐1650 cells were sensitive, H‐460 and H‐1975 cells were resistance to growth inhibition by Ad.mda‐7, which was reversed by the combination of Ad.mda‐7 and gefitinib. This combination increased MDA‐7/IL‐24 and downstream effector double‐stranded RNA‐activated protein kinase (PKR) protein expression, promoting apoptosis induction of NSCLC cells. Inhibition of PKR significantly inhibited apoptosis induction by Ad.mda‐7 when administered alone but not when used in combination with gefitinib. The combination treatment also augmented inhibition of EGFR signaling. Our findings indicate that a combinatorial treatment with Ad.mda‐7 and gefitinib may provide benefit in the treatment of NSCLC, especially in patients displaying resistance to clinically used EGFR inhibitors. J. Cell. Physiol. 210: 549–559, 2007.
- 16 November 2006
- Published by Wiley in Journal of Cellular Physiology
- Vol. 210 (2) , 549-559
Combinatorial treatment of non‐small‐cell lung cancers with gefitinib and Ad.mda‐7 enhances apoptosis‐induction and reverses resistance to a single therapy
Activation of the epidermal growth factor receptor (EGFR) contributes to the pathogenesis of non‐small‐cell lung carcinomas (NSCLC) and gefitinib, a selective reversible EGFR inhibitor, is effective in treating patients with NSCLC. However, clinical resistance to gefitinib is a frequent occurrence highlighting the need for improved therapeutic strategies. Melanoma differentiation associated gene‐7 (mda‐7)/Interleukin‐24 (IL‐24) (mda‐7/IL‐24) displays cancer‐selective apoptosis induction when delivered via a replication‐incompetent adenovirus (Ad.mda‐7). In this study, the effect of Ad.mda‐7 infection, either alone or in combination with gefitinib, was analyzed in a panel of NSCLC cell lines carrying wild‐type EGFR (H‐460 and H‐2030) or mutant EGFR (H‐1650 and H‐1975). While H‐2030 and H‐1650 cells were sensitive, H‐460 and H‐1975 cells were resistance to growth inhibition by Ad.mda‐7, which was reversed by the combination of Ad.mda‐7 and gefitinib. This combination increased MDA‐7/IL‐24 and downstream effector double‐stranded RNA‐activated protein kinase (PKR) protein expression, promoting apoptosis induction of NSCLC cells. Inhibition of PKR significantly inhibited apoptosis induction by Ad.mda‐7 when administered alone but not when used in combination with gefitinib. The combination treatment also augmented inhibition of EGFR signaling. Our findings indicate that a combinatorial treatment with Ad.mda‐7 and gefitinib may provide benefit in the treatment of NSCLC, especially in patients displaying resistance to clinically used EGFR inhibitors. J. Cell. Physiol. 210: 549–559, 2007.